Scorpius Holdings

Aug 14, 2023

•

Jun 30, 2023

Scorpius Holdings Q2 2023 Earnings Report

NightHawk Biosciences reported an increase in revenue from process development and a net loss for Q2 2023.

Key Takeaways

NightHawk Biosciences reported $0.7 million in revenue from process development, an increase compared to the previous year. The company's net loss was $13.9 million, or $0.53 per share. The company had $18.6 million in cash, cash equivalents, and short-term investments as of June 30, 2023.

Revenue from process development increased due to the San Antonio CDMO facility operations.

Research and development expenses increased by 21.3% due to HS-110 expense, ANTHIM, and unallocated research expenses.

Cost of revenues were $0.4 million, reflecting direct costs of labor, overhead, and materials.

Net loss was $13.9 million, or $0.53 per share, compared to $6.8 million, or $0.27 per share in the prior year.